Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript

Core Viewpoint - The company has successfully completed a significant transaction by divesting U.S. rights to Zubsolv to Dexcel Pharma for a total of $91 million, marking a strategic move for the company as it approaches the end of the year [2]. Group 1: Transaction Details - The company sold the U.S. rights to Zubsolv to Dexcel Pharma for a net amount of $91 million [2]. - In addition to the sale price, the company will receive payment for the inventory at the time of closing [2]. - There is a contingent payment agreement that could yield up to $16.8 million, which is structured as an earn-out [3].